Related Experiment Video
Updated: Dec 3, 2025
04:41
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.2K
Protective Variants in Alzheimer's Disease
Shea J Andrews1,2, Brian Fulton-Howard1,2, Alison Goate1
1Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Current Genetic Medicine Reports
|October 29, 2020
Summary
Researchers reviewed protective Alzheimer's disease (AD) variants, identifying key genes like APOE. Few protective variants are well-characterized, necessitating further study to find new protective genetic factors for AD.
Area of Science:
- Genetics and Genomics
- Neuroscience
- Alzheimer's Disease Research
Background:
- Over 40 loci linked to Alzheimer's disease (AD) risk identified in the past decade.
- Previous research predominantly focused on AD risk factors, neglecting protective genetic variations.
Purpose of the Study:
- To review known protective variants associated with Alzheimer's disease (AD).
- To explore the putative mechanisms of action for these protective variants.
- To recommend strategies for identifying novel protective genetic variants in AD.
Main Methods:
- Review of recent Genome-Wide Association Studies (GWAS) and existing literature.
- Analysis of identified common and rare protective variants.
- Discussion of functional evidence and allele frequencies.
Main Results:
- Identification of protective variants in genes including APP, APOE, PLCG2, MS4A, MAPT-KANSL1, RAB10, ABCA1, CCL11, SORL1, NOCT, SCL24A4-RIN3, CASS4, EPHA1, SPPL2A, and NFIC.
- Observation that few protective variants possess strong functional evidence and low derived allele frequencies (<20%).
Conclusions:
- Significant need for additional fine-mapping and multi-omic studies to validate and characterize known AD protective variants.
- Specialized genome-wide scans are recommended for the discovery of novel protective variants.
- Further research is crucial to fully understand the genetic landscape of AD protection.
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.3K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.3K
01:22Alzheimer's Disease: Treatment
624
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
624
01:30Dementia
396
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
396
03:03Amyloid Fibrils
11.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.4K